Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown a slight increase in performance, with a closing rise of 0.79% and a trading volume of 849 million yuan on February 6, 2024 [1]. Group 1: Fund Overview - The Hong Kong Innovative Drug ETF (159567) was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1]. - As of February 5, 2024, the fund's total shares stood at 10.244 billion, with a total size of 7.906 billion yuan, reflecting a 2.36% decrease in shares and a 0.13% increase in size since December 31, 2023 [1]. Group 2: Liquidity and Trading Activity - Over the last 20 trading days, the cumulative trading amount for the ETF reached 21.573 billion yuan, with an average daily trading amount of 1.079 billion yuan [1]. - Since the beginning of the year, the ETF has recorded a cumulative trading amount of 29.237 billion yuan over 25 trading days, averaging 1.169 billion yuan per day [1]. Group 3: Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 56.50% during the management period [1]. Group 4: Top Holdings - The top holdings of the Hong Kong Innovative Drug ETF (159567) include: - CSPC Pharmaceutical Group (10.44% holding, 108 million shares, market value of 825 million yuan) [2] - BeiGene (9.91% holding, 4.8299 million shares, market value of 782 million yuan) [2] - CanSino Biologics (9.72% holding, 7.52 million shares, market value of 768 million yuan) [2] - China Biologic Products (9.66% holding, 13.7 million shares, market value of 763 million yuan) [2] - Innovent Biologics (9.53% holding, 10.9295 million shares, market value of 753 million yuan) [2] - Other notable holdings include 3SBio, Hansoh Pharmaceutical, and Kelun-Biotech [2].

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock price increase of over 15% within the next six months [4]. Core Insights - The company has signed a strategic research and development collaboration agreement with AstraZeneca, granting AstraZeneca exclusive global rights (excluding Greater China) to the company's weight management product portfolio, including a clinical-ready project SYH2082 and three preclinical projects. The company will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and $13.8 billion for sales, along with a double-digit percentage royalty on net sales [1][2]. - The collaboration marks an upgrade from single product licensing to platform licensing, reflecting AstraZeneca's strong recognition of the company's long-acting peptide and AI pharmaceutical technology platforms [1]. - The company is advancing its proprietary sustained-release drug delivery technology and AI drug discovery platform, which enhances patient compliance by allowing for monthly or longer dosing intervals [2]. Financial Summary - The company's projected revenues for 2025-2027 are estimated at 28.8 billion, 35.9 billion, and 32.5 billion CNY, respectively, with a compound annual growth rate (CAGR) of 24.62% in 2026 [3]. - The net profit attributable to the parent company is forecasted to be 5.34 billion, 7.87 billion, and 6.76 billion CNY for 2025-2027, with corresponding earnings per share (EPS) of 0.46, 0.68, and 0.59 CNY [3]. - The current market capitalization is approximately 112.23 billion HKD, with a total share count of 11,522 million [4].

Core Viewpoint - The Hong Kong Dividend ETF (工银, 159691) experienced significant net redemptions, indicating a trend of outflow from this fund, which may reflect investor sentiment and market conditions [1][2]. Fund Performance - As of February 3, the latest scale of the Hong Kong Dividend ETF is 85.4 billion yuan, with a net outflow of 28.23 million yuan on that day, representing 0.33% of the previous day's scale [1]. - Over the past five days, the fund faced net redemptions totaling 68.26 million yuan, ranking 15th out of 212 in cross-border ETF net outflows [1]. - In the last ten days, the total net redemptions reached 202 million yuan, ranking 7th out of 212 [1]. - Over the past 20 days, the fund saw net redemptions of 332 million yuan, ranking 8th out of 212 [1]. Fund Size and Liquidity - The current share count of the Hong Kong Dividend ETF is 6.282 billion shares, with a scale of 85.4 billion yuan, showing a 3.80% decrease in shares and a 1.24% increase in scale since December 31, 2025 [2]. - The cumulative trading amount over the last 20 trading days is 6.501 billion yuan, with an average daily trading amount of 325 million yuan [2]. - Year-to-date, the cumulative trading amount is 7.151 billion yuan, with an average daily trading amount of 325 million yuan [2]. Fund Management - The current fund managers are Liu Weilin and He Shun, with Liu managing since March 30, 2023, achieving a return of 36.96%, while He is set to manage from May 30, 2024, with a return of 14.67% [2]. Top Holdings - The fund's top holdings include: - China National Offshore Oil Corporation (14.55% holding) - China Shenhua Energy (9.65% holding) - China Pacific Insurance (8.90% holding) - China Hongqiao Group (7.68% holding) - CLP Holdings (7.53% holding) - WH Group (7.36% holding) - Power Assets Holdings (6.21% holding) - Haier Smart Home (3.50% holding) - People's Insurance Company of China (3.42% holding) - CSPC Pharmaceutical Group (3.41% holding) [2].

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

Group 1 - The core viewpoint is that various institutions maintain "buy" ratings for different companies, highlighting their growth potential and strategic partnerships [1][2][3][4][5][6][7][8][9][10] Group 2 - China-based pharmaceutical company, Stone Pharmaceutical Group, has entered a significant $18.5 billion strategic collaboration with AstraZeneca, focusing on long-acting GLP-1/GIPR dual-target peptides and multiple obesity/diabetes pipelines, enhancing its AI-driven drug discovery capabilities [1][2] - Baidu Group's cloud business has shown a 10% year-on-year growth in Q4, driven by intelligent cloud infrastructure, with AI-native marketing services now covering 70% of search result pages [3] - Sunny Optical Technology is projected to see a 70-75% increase in net profit by 2025, benefiting from improved ASP and gross margin in mobile lenses and modules [4] - InSilico Medicine has secured over HKD 930 million in cardiovascular metabolic collaborations, continuing its partnerships with major pharmaceutical companies, and has produced 27 preclinical candidate molecules through its Pharma.AI platform [5][6] - Kuaishou Technology is enhancing its platform with advanced AI models, which are expected to improve user engagement and profitability [6] - Decon Agriculture is expected to achieve a target price of HKD 87, with a stable cost structure and leading efficiency in pig farming [7] - Dongfang Zhenxuan has exceeded profit expectations by 68% in the first half of FY26, with self-operated product GMV rising to 52.8% [8] - Hang Lung Properties is experiencing a recovery in retail sales, with Q3/Q4 growth rates of 10% and 18%, respectively, and an improved tenant mix [10]

Group 1 - The core viewpoint of the report is that Citibank reaffirms its "highly confident outperform" rating for CSPC Pharmaceutical Group (01093), raising the target price from HKD 17.4 to HKD 19 [1] - The bank anticipates that the business development (BD) transactions completed by CSPC will start converting into recurring revenue from this year [1] - CSPC has entered into four significant BD transactions with AstraZeneca (AZN.US) and Madrigal Pharmaceuticals (MDGL.US), expected to generate approximately USD 10.2 billion in upfront and milestone payments, significantly boosting profits from 2025 to 2027 to RMB 6.3 billion, RMB 10.2 billion, and RMB 10.9 billion respectively [1] Group 2 - The bank has adjusted its profit forecasts for CSPC for 2025 to 2027, decreasing the 2025 estimate by 2.4%, increasing the 2026 estimate by 8.2%, and increasing the 2027 estimate by 53.7%, reflecting the financial impact of the BD transactions after risk adjustments [1] - CSPC is currently trading at a forecasted price-to-earnings ratio of 9.2 times for 2026, significantly lower than the industry median of 16.4 times [1]

Core Viewpoint - Citi has reiterated its "highly confident outperform" rating for CSPC Pharmaceutical Group (01093), raising the target price from HKD 17.4 to HKD 19, anticipating that the business development (BD) transactions completed by CSPC will convert into recurring revenue starting this year [1] Group 1: Business Development Transactions - CSPC has completed four significant BD transactions with AstraZeneca (AZN.US) and Madrigal Pharmaceuticals (MDGL.US), expected to generate approximately USD 10.2 billion in upfront and milestone payments, which will significantly boost profits from 2025 to 2027 [1] - The projected profits for CSPC are expected to rise to RMB 6.3 billion, RMB 10.2 billion, and RMB 10.9 billion for the years 2025, 2026, and 2027 respectively [1] Group 2: Financial Forecast Adjustments - The financial forecasts for CSPC have been adjusted, with profit estimates for 2025, 2026, and 2027 being decreased by 2.4%, increased by 8.2%, and increased by 53.7% respectively, reflecting the financial impact of the BD transactions after risk adjustments [1] - CSPC is currently trading at a forecasted price-to-earnings ratio of 9.2 times for 2026, significantly lower than the industry median of 16.4 times [1]

Investment Rating - The report provides a positive outlook for CSPC Pharmaceutical Group, indicating a clear roadmap for internationalization and significant revenue growth expected from completed business development transactions by 2026 [5][6]. Core Insights - CSPC is projected to convert its completed business development transactions into recurring revenue by 2026, supported by major research milestones and successful overseas development progress [6]. - The company has secured approximately $10.2 billion in upfront and milestone payments from significant partnerships with AstraZeneca and Madrigal, which are expected to enhance profitability from 2025 to 2027 [5][6]. - Key products such as KN026 and SYS6010 are anticipated to drive domestic business recovery and accelerate growth post-2027 [7]. Summary by Sections Business Development and Revenue - CSPC's completed business development transactions are expected to yield around $9 billion in free cash flow from milestone payments by 2030, with AstraZeneca's recent $1.2 billion non-refundable upfront payment being a significant contributor [6]. - The company has established eight innovative R&D platforms, transitioning from a raw material producer to a complex generics and innovative drug enterprise, achieving a compound annual growth rate of 3.1% in profitability from 2019 to 2023 [10]. Market Position and Financials - As of February 2, 2026, CSPC's stock price was HKD 9.15, with a market capitalization of $13.54 billion [13]. - The company ranks among the top ten in the Chinese pharmaceutical industry by drug revenue, with a significant portion of its income derived from the Asian market [11]. Catalysts for Growth - Key catalysts include the progress of overseas R&D projects, particularly the core product EGFR ADC, and the clinical development plans of major partners like AstraZeneca [8]. - The anticipated launch of innovative drugs and the entry of early-stage products into clinical phases are expected to validate the company's R&D capabilities [8].

Group 1 - The stock price of CSPC Pharmaceutical Group (01093.HK) increased by nearly 6%, reaching HKD 9.69 per share [2] - The trading volume amounted to HKD 1.173 billion [2]